Skip to content
OpenCapital
Get started

AbbVie ABBV Botox Therapeutic — Net revenues

Other product segments

Skyrizi
$4.48B+30.9%
Rinvoq
$2.12B+23.3%
All other
$1.03B-18.2%
Vraylar
$905M+18.3%
Venclexta
$770M+15.8%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Imbruvica
$556M-24.7%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Vyalev
$201M+219%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

Evolus logo
EOLSProduct revenue, net — Total net revenues
$72.75M+6.9%
Amneal Pharmaceuticals, Inc. logo
AMRXSubtotal therapeutic classes — Net revenue
$133.27M+23.1%
Merit Medical Systems logo
MMSITherapeutic — Revenue
$126.4M+9.9%
Amneal Pharmaceuticals, Inc. logo
AMRXOther therapeutic classes — Net revenue
$13.95M+115%
Bioventus logo
BVSRestorative Therapies — Total Net Sales
$20.64M+4.6%
Alpha Cognition logo
ACOGProduct Net — Revenue
$3.5M+910%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's botox therapeutic — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's botox therapeutic — net revenues?
AbbVie (ABBV) reported botox therapeutic — net revenues of $1.01B in Q1 2026.
How has AbbVie's botox therapeutic — net revenues changed year-over-year?
AbbVie's botox therapeutic — net revenues increased by 16.5% year-over-year, from $866M to $1.01B.
What is the long-term trend for AbbVie's botox therapeutic — net revenues?
Over 4 years (2021 to 2025), AbbVie's botox therapeutic — net revenues has grown at a 11.4% compound annual growth rate (CAGR), from $2.45B to $3.77B.
What does botox therapeutic — net revenues mean?
This metric represents the total gross sales of the therapeutic-indicated Botox product line, adjusted for returns, allowances, and rebates. It reflects the commercial performance and market adoption of the drug within medical and clinical treatment settings, excluding aesthetic applications. This revenue stream is a critical indicator of the company's footprint in the neurotoxin and specialty pharmaceutical market.